BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment

On May 19, BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced promising results from its Phase 3 trial of Acoramidis, showing its ability to increase serum transthyretin (TTR) levels and significantly reduce mortality risk in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The study revealed that a 5-mg/dL rise in TTR within 28 days led to a mortality risk reduction of up to 31.6% over 30 months. The drug, branded as Attruby in the U.S. and BEYONTTRA in Europe, showed rapid and sustained benefits for both variant and wild-type ATTR-CM patients, with noticeable improvements as early as three months.

Stock market data on a laptop screen. Photo by Alesia Kozik on Pexels

Long-term data from the 42-month open-label extension demonstrated that maintaining stable TTR levels significantly lowered all-cause mortality and hospitalizations due to cardiovascular issues. These findings position serum TTR as a critical biomarker for guiding treatment decisions in ATTR-CM patients. Acoramidis is now approved globally.

Some adverse reactions were also noted, including diarrhea (11.6% vs. 7.6%) and upper abdominal pain (5.5% vs. 1.4%), raising concerns about bearability among patients. Moreover, reliance on third-party development poses risks to its commercialization. Despite these challenges, Acoramidis marks a significant breakthrough in ATTR-CM treatment, providing renewed optimism for patients.

Acoramidis, marketed as Attruby in the U.S. and BEYONTTRA in Europe, is a TTR stabilizer used to treat ATTR-CM. It rapidly increases serum TTR levels, improving clinical outcomes and reducing all-cause mortality and cardiovascular-related hospitalizations. Studies confirm its effectiveness in lowering mortality risk through enhanced TTR stabilization. Common side effects include diarrhea and upper abdominal pain, though most are mild and do not require discontinuation.

While we acknowledge the potential of BridgeBio Pharma, Inc. (NASDAQ:BBIO) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BBIO and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None.